Table 1.
Baseline characteristics
| Characteristic | Tirzepatide (n = 364) | Placebo (n = 367) |
|---|---|---|
| Age (years) | 65.5 ± 10.5 | 65.0 ± 10.9 |
| Women | 200 (54.9%) | 193 (52.6%) |
| Race | ||
| American Indian, Alaska Native or Pacific Islanders | 26 (7.1%) | 24 (6.5%) |
| Asian | 58 (15.9%) | 73 (19.9) |
| Black or African American | 22 (6.0%) | 14 (3.8%) |
| White | 256 (70.3%) | 256 (69.8%) |
| Other or mixed race | 2 (0.5%) | 0 (0.0%) |
| Ethnicity | ||
| Hispanic or Latino | 195 (53.6%) | 205 (55.9%) |
| Not Hispanic or Latino | 164 (45.1%) | 159 (43.3%) |
| Region | ||
| United States | 83 (22.8%) | 68 (18.5%) |
| Latin America | 193 (53.0%) | 197 (53.7%) |
| Asia | 58 (15.9%) | 73 (19.9%) |
| Other | 30 (8.2%) | 29 (7.9%) |
| Measures of adiposity | ||
| Body weight (kg) | 102.9 ± 21.7 | 103.1 ± 22.7 |
| BMI (kg m−2) | 38.3 ± 6.4 | 38.2 ± 7.0 |
| Waist circumference (cm) | 120 ± 15 | 120 ± 14 |
| HFpEF severity and phenotyping | ||
| NYHA Class II | 262 (72.0%) | 268 (73.0%) |
| NYHA Class III–IV | 102 (28.0%) | 99 (27.0%) |
| NT-proBNP, median (IQR), ng l−1 | 196 (56, 488) | 169 (64, 476) |
| KCCQ-CSS score | 53.9 ± 17.9 | 53.2 ± 19.0 |
| 6MWD (m) | 305.0 ± 80.0 | 300.6 ± 83.5 |
| Left ventricular ejection fraction (%) | 61.0 ± 6.5 | 60.6 ± 6.2 |
| High-sensitivity troponin T, median (IQR), (ng l−1) | 11 (7–19) | 12 (8–19) |
| Elevated troponin T (>14 ng l−1), n (%) | 151 (42.2%) | 147 (40.6%) |
| Current atrial fibrillation, n (%) | 95 (26.1%) | 91 (24.8%) |
| Cardiovascular history | ||
| Hospitalization for HF within 12 months | 171 (47.0%) | 172 (46.9%) |
| Diabetes mellitus | 174 (47.8%) | 178 (48.5%) |
| Coronary artery disease | 111 (30.9%) | 106 (29.1%) |
| Cardiovascular medications | ||
| Diuretics | 267 (73.4%) | 271 (73.8%) |
| RAS and neprilysin inhibitors | 293 (80.5%) | 295 (80.4%) |
| Beta blocker | 245 (67.3%) | 263 (71.7%) |
| Mineralocorticoid receptor antagonist | 131 (36.0%) | 125 (34.1%) |
| Sodium–glucose cotransporter 2 inhibitor | 69 (19.0%) | 57 (15.5%) |
Plus–minus values are mean ± s.d. The numbers in parentheses are percentages or IQR. Race was self-reported; patients who identified with ≥1 race or with no race were classified as other. Renin–angiotensin system (RAS) inhibitors include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and angiotensin receptor neprilysin inhibitors.